The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows: Group I: Patients with stable disease Group II: Patients with metastasis and relapse In patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry